Triptorelin 11.25 mg

DRUG2 trials

Sponsors

Ipsen, Martin Blomberg Jensen

Conditions

Bone MarkersMenopausal OsteoporosisProstate Cancer

Phase 2

COMPASS - COpenhagen MenoPAuSe Study

RecruitingNCT07254429

Martin Blomberg JensenBone Markers, Menopausal Osteoporosis

Start: 2025-10-02End: 2028-05-01Target: 192Updated: 2026-03-02

Phase 4

A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.

CompletedNCT01753297

IpsenProstate Cancer

Start: 2012-12-11End: 2019-09-09Updated: 2020-12-09

Related Papers

PRIORITI: Phase 4 study of triptorelin or active surveillance in high‐risk prostate cancer

Asia-Pacific Journal of Clinical Oncology2024-07-031 citations